Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters

  • Authors:
    • Kai Gao
    • Xiaorong Li
    • Gui Hu
    • Kaiyan Yang
    • Buning Tian
    • Yi Zhang
  • View Affiliations

  • Published online on: August 6, 2012     https://doi.org/10.3892/ol.2012.854
  • Pages: 988-992
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Deleted in liver cancer 2 (DLC2) has been identified as a tumor suppressor gene. DLC2 is closely related to deleted in liver cancer 1 (DLC1) and is located at chromosome 13q12.3. The expression of DLC2 mRNA has been found in a wide range of cancers, including colorectal cancer (CRC). However, there are no available data on the expression status of DLC2 in Chinese patients with CRC and its correlation with clinicopathological parameters. The aim of this study was to investigate the expression levels of DLC2 mRNA and protein in Chinese patients with CRC and the correlation between DLC2 expression and clinicopathological parameters. To this end, real-time PCR, western blotting and immunohistochemistry were employed to detect DLC2 mRNA and protein expression in CRC and pericarcinomatous intestinal tissue (PCIT) specimens, which were obtained from 102 Chinese CRC patients who underwent surgical resection between October 2010 and February 2012. We also analyzed the correlations between DLC2 expression and the clinicopathological parameters of CRC patients. Our results showed that CRC tissues had significantly lower levels of DLC2 mRNA compared with PCITs (P<0.05); however, the protein expression levels were not significantly different between CRCs and PCITs. The expression levels of DLC2 mRNA and protein were significantly correlated with lymph node metastasis and tumor TNM stage. Additionally, DLC2 mRNA expression levels were also correlated with tumor histopathological degree (P<0.05). Collectively, our results suggest that the downregulated expression of DLC2 participates in CRC carcinogenesis, invasion and lymph node metastasis. Furthermore, our results imply that DLC2 is be a potential prognostic marker for CRC patients.
View Figures
View References

Related Articles

Journal Cover

November 2012
Volume 4 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gao K, Li X, Hu G, Yang K, Tian B and Zhang Y: Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters. Oncol Lett 4: 988-992, 2012
APA
Gao, K., Li, X., Hu, G., Yang, K., Tian, B., & Zhang, Y. (2012). Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters. Oncology Letters, 4, 988-992. https://doi.org/10.3892/ol.2012.854
MLA
Gao, K., Li, X., Hu, G., Yang, K., Tian, B., Zhang, Y."Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters". Oncology Letters 4.5 (2012): 988-992.
Chicago
Gao, K., Li, X., Hu, G., Yang, K., Tian, B., Zhang, Y."Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters". Oncology Letters 4, no. 5 (2012): 988-992. https://doi.org/10.3892/ol.2012.854